Researchers evaluated the frequency of severe and nonsevere relapses among patients with giant cell arteritis and assessed the characteristics associated with severe relapse.

These are symptoms of temporal arteritis, which can develop in people with PMR. (Photo credit: E+/Getty Images) Under the new criteria developed by the American College of Rheumatology and the ...

AbbVie's star immunology drug Rinvoq picked up its seventh FDA approval< | AbbVie's Rinvoq has racked up seven FDA approvals ...

The phase 3 SELECT-GCA study evaluated the efficacy and safety of upadacitinib in patients 50 years of age and older with GCA.

By Denny Jacob AbbVie disclosed positive top-line results from a study on upadacitinib to treat adults with giant cell arteritis, an autoimmune disease.

Giant cell arteritis, also known as temporal arteritis, is an autoimmune disease that causes inflammation of the temporal and other cranial arteries, the aorta, and other large and medium arteries.

According to results of the study, 46% of patients with giant cell arteritis administered Rinvoq achieved sustained remission ...

AbbVie (NYSE: ABBV) today announced positive top-line results from SELECT-GCA, a Phase 3, multicenter, randomized, double-blind, placebo-controlled study, showing upadacitinib (RINVOQ®; 15 mg, once ...

Thursday announced positive results from SELECT-GCA Phase 3 of Upadacitinib 15 mg, once daily in combination with ...

Findings showed 46% of patients who received upadacitinib 15mg achieved sustained remission at week 52 compared with 29% of patients who received placebo. Patients with giant cell arteritis (GCA ...